Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters
Yasser Abuetabh, Mya A. Schmidt, Masaaki Naganuma, Ramana Vaka, Mahmoud A. El-Ghiaty, Shelly Braun, Ethan A. Kwan, Matthieu C.P. Zolondek, Darius Sahid, Laibah Khan, Rajat K. Shandal, Ashley L. Trudeau, Yaning Li, Sufyan O. Malik, Qiuyu Sun, Danica K. Roth, Daniela Y. Morales-Llamas, Jody L. Levasseur, Mourad Ferdaoussi, Richard P. Fahlman, Jason R.B. Dyck
Yasser Abuetabh, Mya A. Schmidt, Masaaki Naganuma, Ramana Vaka, Mahmoud A. El-Ghiaty, Shelly Braun, Ethan A. Kwan, Matthieu C.P. Zolondek, Darius Sahid, Laibah Khan, Rajat K. Shandal, Ashley L. Trudeau, Yaning Li, Sufyan O. Malik, Qiuyu Sun, Danica K. Roth, Daniela Y. Morales-Llamas, Jody L. Levasseur, Mourad Ferdaoussi, Richard P. Fahlman, Jason R.B. Dyck
View: Text | PDF
Research Article Metabolism Muscle biology

Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters

  • Text
  • PDF
Abstract

While glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide are effective in treating obesity, up to 45% of the resulting weight loss can be attributed to skeletal muscle loss. Given the critical role of skeletal muscle in health and mobility, this may have long-term adverse consequences. Herein we investigated whether oral ketone ester supplementation could prevent semaglutide-induced muscle loss and explored the underlying molecular mechanisms. Obese, glucose-intolerant mice received vehicle, semaglutide, or semaglutide plus a β-hydroxybutyrate–generating ketone ester for 3 weeks. Body composition, muscle strength, and endurance were assessed longitudinally. Semaglutide monotherapy reduced lean mass, impaired muscle strength, and suppressed mitochondrial gene expression while elevating atrophy-related genes in skeletal muscle samples. Co-administration with ketone ester preserved skeletal muscle mass and function without compromising fat loss. Mechanistically, ketone ester cotreatment prevented semaglutide-induced changes in mitochondrial and atrophy-related gene expression, suggesting that mitochondrial defects and impaired ketone metabolism contribute to GLP-1RA–induced muscle loss. Together, these findings demonstrate that ketone ester supplementation can maintain muscle mass and performance during semaglutide-driven weight loss. These preclinical findings support ketone therapy as a promising strategy to counteract the sarcopenia-promoting effects of GLP-1RAs and warrant clinical evaluation to assess its translational potential.

Authors

Yasser Abuetabh, Mya A. Schmidt, Masaaki Naganuma, Ramana Vaka, Mahmoud A. El-Ghiaty, Shelly Braun, Ethan A. Kwan, Matthieu C.P. Zolondek, Darius Sahid, Laibah Khan, Rajat K. Shandal, Ashley L. Trudeau, Yaning Li, Sufyan O. Malik, Qiuyu Sun, Danica K. Roth, Daniela Y. Morales-Llamas, Jody L. Levasseur, Mourad Ferdaoussi, Richard P. Fahlman, Jason R.B. Dyck

×

Figure 5

Ketone ester co-therapy prevents semaglutide-induced transcriptomic shifts in skeletal muscle involving proteostasis, translation, and mitochondrial pathways.

Options: View larger image (or click on image) Download as PowerPoint
Ketone ester co-therapy prevents semaglutide-induced transcriptomic shif...
(A) A triplot depicting log2 fold changes in gene expression across vehicle (V), semaglutide (S), and semaglutide + ketone ester (S+K) treatment groups. Genes highlighted in color are significantly altered (P < 0.05, fold change > 1.5), while gray crosses represent genes that are not significantly altered as assessed by ANOVA analysis. Genes are grouped into 5 distinct clusters based on expression trajectories: mitochondrial-enriched (yellow), muscle contractility–enriched (orange), translation-enriched (purple), proteostasis-enriched (teal), and extracellular matrix–enriched (green). The membership scale denotes how close to the trend each gene falls within the cluster. (B–G) Soft clustering of differentially expressed genes showing relative gene expression trends of interest: proteostasis-enriched cluster (B), translation-enriched cluster (D), and mitochondrial-enriched cluster (F), across V, S, and S+K conditions. Gene Ontology (GO) analysis presented in dot plots is located below differentially expressed gene cluster graphs (C, E, and G). Bubble size reflects the number of genes associated with each GO term; x axis indicates statistical significance as –log10 (P value). (H) Heatmaps of mitochondrial electron transport chain– and atrophy-related genes (n = 3). RNA-seq data were processed via 1-way ANOVA (P < 0.05, fold change ≥ 1.5). Heatmaps were generated using row-wise z score normalization of expression values. Data presented in the figure were obtained from experiments performed on male C57BL/6N mice.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts